Clinical Research of the Prognostic Influence of NSAIDS's Anti-inflammatory Effect on Senior Patients With Hip Fracture
1 other identifier
observational
800
1 country
1
Brief Summary
With the development of society, aged population is growing. Hip fracture is the most common disease for aged people. With the life being longer than before, incidence of this disease is growing. The mortality of this disease is high-- almost 10% patients will die within 1 month, about 1/3 of patients will die within 12 months. About 20%-30% aged people who have hip fracture will die within one year. The damaged organs caused by excessive inflammatory is one of possible reasons to cause higher mortality. Therefore, the investigators imagined that if they gave medicines to patients in time to reduce the inflammatory level, the inflammatory might have less effects on organs, and the recovery could be improved. The investigators hypothesis on the basic research: the anti-inflammatory function of non steroidal antiinflammatory drugs (NSAIDs) can inhibit the inflammatory level of elderly hip fracture, so as to improve the recovery level and reduce the complicating disease and mortality. The investigators designed a clinic study to research NSAIDS' effects on inflammatory level and prognosis of elderly hip fracture.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2012
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2012
CompletedFirst Submitted
Initial submission to the registry
February 13, 2012
CompletedFirst Posted
Study publicly available on registry
April 24, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2013
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2015
CompletedApril 24, 2012
April 1, 2012
1.9 years
February 13, 2012
April 21, 2012
Conditions
Keywords
Interventions
200mg, PO.Bid, last from admission to hospital to one week after operation.
1 tablet(Acetaminophen 325mg oxycodone 5mg), Q6h orally take,last from admission to hospital to one week after operation.
Eligibility Criteria
Elderly patients(age \> 60 years old)with hip fracture(intertrochanteric fractures and femoral neck fractures)adimited into Beijing Army General Hospital
You may qualify if:
- age \> 60 years old,
- new patients with hip fracture(intertrochanteric fractures and femoral neck fractures),
- sign informed consent,
- can be followed up
You may not qualify if:
- have autoimmune disease,
- with blood disease, a history of thrombosis,
- with sulfonamides, aspirin or celebrex race Levin allergies,
- pathological fracture
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Beijing Army General Hospital
Beijing, Beijing Municipality, 100700, China
Biospecimen
Peripheral blood serum
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Tiangsheng Sun, Prof.
Beijing Army General Hospital
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER GOV
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Li Shaoguang
Study Record Dates
First Submitted
February 13, 2012
First Posted
April 24, 2012
Study Start
January 1, 2012
Primary Completion
December 1, 2013
Study Completion
December 1, 2015
Last Updated
April 24, 2012
Record last verified: 2012-04